<DOC>
	<DOCNO>NCT01911611</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled study evaluate safety , tolerability , pharmacokinetics RO6870868 healthy volunteer . Subjects randomize receive single ascending dos either RO6870868 placebo , without food .</brief_summary>
	<brief_title>A Study RO6870868 Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Healthy male female subject , 18 65 year age , inclusive . Healthy status define absence evidence active chronic disease follow detailed medical surgical history complete physical examination Women nonchildbearing potential include woman undergone hysterectomy bilateral oophorectomy postmenopausal females Male subject must willing use effective contraception define protocol duration study one month last dose study medication Body Mass Index ( BMI ) screen 18 32 kg/m2 , inclusive Nonsmokers , use &lt; 10 cigarette ( equivalent nicotinecontaining product ) per day No medical social condition would potentially interfere subject ability comply study visit schedule study assessment Pregnant ( positive pregnancy test ) lactate woman , male partner woman pregnant lactating History drug alcohol abuse within last year History immunologically mediate disease History symptom significant disease include ( limited ) neurological , cardiovascular , endocrine , respiratory , gastrointestinal , hepatic , renal disorder Personal family history congenital long QT syndrome sudden death Evidence active suspect cancer history malignancy investigator 's opinion , risk recurrence . History receive systemic antineoplastic ( include radiation ) immunomodulatory treatment ( include systemic oral inhaled corticosteroid ) &lt; /= 6 month prior first dose study drug expectation treatment need time study Any confirm significant allergic reaction ( urticaria anaphylaxis ) drug , multiple drug allergy ( nonactive hay fever acceptable ) History significant psychiatric disease Significant acute infection , e.g. , influenza , local infection , acute gastrointestinal symptom clinically significant illness within two week dose administration History gastrointestinal disease include inflammatory bowel disease , peptic ulcer disease , gastrointestinal hemorrhage Inadequate hematologic , renal liver function Positive hepatitis A , hepatitis B , hepatitis C , HIV infection History ( within 3 month screen ) alcohol consumption exceed 14 unit per week average ( 1 unit = 10 gram alcohol ) . Alcohol consumption prohibit least 48 hour screen , 48 hour admission , 48 hour dose , 48 hour schedule visit Any clinically significant concomitant disease condition could interfere , treatment might interfere , conduct study , would , opinion investigator , pose unacceptable risk subject study Subjects receive IFN peginterferon within 8 week prior dose Participation clinical study new chemical entity within 60 day prior study randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>